Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- HTHT +9.4%, HIVE +8.8%, AMPG +1.9% (guidance), PPTA +1.8%
Other news:
- OABI +20.1% (signs ion channel collaboration and license deal with Eli Lilly; raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity)
- ARGX +10.5% (reports topline results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis)
- PURR +9.3% (Duquesne (Stanley Druckenmiller) discloses new postion)
- MESO +8.7% (completes patient treatment in pivotal Phase III chronic low back pain trial)
- DSX +7.7% (Diana Shipping withdraws bid for Genco after board demanded higher terms) IPCX +6.3% (closes A1R water merger; combined company to trade as WATR on Aug. 17)
- HCM +6.3% (says ORPATHYS plus AstraZeneca's TAGRISSO met PFS and OS goals in Phase III lung cancer trial)
- FULC +4.8% (to merge with Slate Medicines in all-stock deal; backs transaction with $245 mln private placement)
- SLN +4.2% (closes upsized ADS offering with full underwriters' option exercise)
- NPK +4% (AMTEC Corporation announces option awards under AMTEC's current five-year 40mm systems contract)
- EYPT +3.5% (says Phase III LUGANO missed primary endpoint in full dataset; DURAVYU showed non-inferiority in ad hoc analysis)
- CRWV +2.5% (Appaloosa (David Tepper) discloses new position)
- TTMI +2.5% (to acquire Epiq Solutions for about $1.1 bln in cash)
- FTAI +2.2% (closes $2.0 bln warehouse financing facility for second Strategic Capital vehicle) IMC +2% (files for 10.11 mln ordinary share offering by selling shareholder)
- INTC +1.6% (CEO Lip-Bu Tan bought 105,263 shares at $95 worth ~$10 mln)
- GT +1.3% (Appaloosa (David Tepper) discloses new position)
- PAYP +1.3% (ValueAct discloses new stake)